Introduction: Advanced malignant pleural mesothelioma (MPM) is generally treated with platinum/pemetrexed-based first-line therapy. Once the disease progresses, evidence for the efficacy of palliative treatments is lacking, and platinum re-challenge or single-agent chemotherapy are commonly used. To assess the effects of cytostatic or targeted therapy for treating MPM, we performed a systematic review and meta-analysis.
Material And Methods: PubMed, the Cochrane Library, and Embase databases were searched to identify published articles on second-line treatments for recurrent or advanced mesothelioma. Inclusion criteria were publication in the English language, describing clinical trials with 20 or more patients, and evaluability for efficacy and for receiving second-line systemic therapies. Data were pooled using number of events/number of evaluable patients, median overall survival (OS) and progression-free survival (PFS), according to a fixed or random effect model. Pooled median OS was the primary endpoint.
Results: A total of 49 eligible studies (n = 3938 patients; range, 12-400) were identified. Median progression-free survival (PFS) was 3.4 months (95%CI 2.87-3.93). Median pooled OS was 7.86 (95%CI 7.01-8.72). The pooled overall response rate (ORR) was 8.63% (95%CI 6-11.26), and the pooled disease control rate (DCR) was 54.8% (95%CI 48.9-60.6). Median pooled OS with platinum- and pemetrexed-based chemotherapy were 7.93 and 7.78 months, respectively.
Conclusions: There remains uncertainty about the ideal second-line agent for MPM. Based on this meta-analysis, palliative chemotherapy or other experimental agents can be considered for patients with MPM who desire further treatment after their disease has progressed, during or after first-line therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rmed.2018.06.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis.
Cancer Treat Rev
January 2025
Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, Charlottesville, VA, United States. Electronic address:
Background: Trastuzumab deruxtecan (T-DXd) has shown promising activity in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and central nervous system (CNS) involvement. In this updated meta-analysis, we explore the effectiveness of T-DXd in a large subset of patients with HER2-positive BC and CNS disease.
Methods: A systematic search was made on September 16th, 2024, for studies investigating T-DXd in the scenario of HER2-positive BC and brain metastases (BMs) and/or leptomeningeal disease (LMD).
Evaluating Delta-8-THC-Induced Psychosis: A Systematic Review.
Clin Neuropharmacol
January 2025
Eastern Virginia Medical School, Norfolk, VA.
Objectives: This study reviews literature on the psychiatric effects of delta-8-THC, particularly psychosis and severe mental health outcomes, to highlight the need for further research and regulation.
Background: Marijuana, the most widely used illicit drug in the United States, sees increasing use due to legalization. Although moderate use is generally safe, adverse effects can occur, especially in those with preexisting conditions.
Comparative Safety of Istradefylline Among Parkinson Disease Adjunctive Therapies: A Systematic Review and Meta-analysis of Randomized Controlled Studies.
Clin Neuropharmacol
January 2025
MedStar Georgetown University Hospital, Washington, DC.
Introduction: Adjunctive therapies to treat OFF episodes resulting from long-term levodopa treatment in Parkinson disease (PD) are hampered by safety and tolerability issues. Istradefylline offers an alternative mechanism (adenosine A2A receptor antagonist) and therefore potentially improved tolerability.
Methods: A systematic review of PD adjuncts published in 2011 was updated to include randomized controlled trials published from January 1, 2010-April 15, 2019.
Effectiveness of Synchronous Postdischarge Contacts on Health Care Use and Patient Satisfaction : A Systematic Review and Meta-analysis.
Ann Intern Med
January 2025
Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System; Department of Population Health Sciences, Duke University School of Medicine; and Durham Evidence Synthesis Program, Durham Veterans Affairs Health Care System, Durham, North Carolina (J.M.G.).
Background: Postdischarge contacts (PDCs) after hospitalization are common practice, but their effectiveness in reducing use of acute care after discharge remains unclear.
Purpose: To assess the effects of PDC on 30-day emergency department (ED) visits, 30-day hospital readmissions, and patient satisfaction.
Data Sources: MEDLINE, Embase, and CINAHL searched from 2012 to 25 May 2023.
Resection of a ventrally located ossified thoracic spinal meningioma: illustrative case.
J Neurosurg Case Lessons
January 2025
Division of Neurosurgery, Department of Surgery, Hospital Ignacio Pirovano, Buenos Aires, Argentina.
Background: Resection of calcified meningiomas in the ventral thoracic spinal canal remains a formidable surgical challenge despite advances in technology and refined microsurgical techniques. These tumors, which account for a small percentage of spinal meningiomas, are characterized by their hardness, complicating safe resection and often resulting in worse outcomes than their noncalcified counterparts.
Observations: The authors present the case of a 68-year-old woman with a ventrally located ossified meningioma at the T9-10 level, successfully treated via a posterolateral transpedicular approach.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!